Last reviewed · How we verify
The methylprednisolone sodium succinate
Methylprednisolone sodium succinate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators.
Methylprednisolone sodium succinate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators. Used for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (e.g. psoriasis, eczema).
At a glance
| Generic name | The methylprednisolone sodium succinate |
|---|---|
| Sponsor | Tang-Du Hospital |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to glucocorticoid receptors in the cytoplasm, which then translocate to the nucleus and inhibit the transcription of genes involved in inflammation. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Approved indications
- Severe asthma attacks
- Severe allergic reactions (anaphylaxis)
- Severe skin conditions (e.g. psoriasis, eczema)
- Severe inflammatory conditions (e.g. rheumatoid arthritis, lupus)
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Increased blood pressure
- Weight gain
- Osteoporosis
- Glaucoma
- Cataracts
- Hypokalemia
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The methylprednisolone sodium succinate CI brief — competitive landscape report
- The methylprednisolone sodium succinate updates RSS · CI watch RSS
- Tang-Du Hospital portfolio CI